CY1116379T1 - Συζευγμενοι vi σακχαριτες - Google Patents
Συζευγμενοι vi σακχαριτεςInfo
- Publication number
- CY1116379T1 CY1116379T1 CY20151100416T CY151100416T CY1116379T1 CY 1116379 T1 CY1116379 T1 CY 1116379T1 CY 20151100416 T CY20151100416 T CY 20151100416T CY 151100416 T CY151100416 T CY 151100416T CY 1116379 T1 CY1116379 T1 CY 1116379T1
- Authority
- CY
- Cyprus
- Prior art keywords
- sacraries
- cognitive
- derivatized
- crm197
- conjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Δύο συζεύγματα Vi έχουν παρασκευαστεί με σύνθεση μέσω καρβοδιιμιδίου, χρησιμοποιώντας παραγωγοποιημένη με διυδραζίδιο αδιπικού οξέος CRM197 (μια μη τοξική παραλλαγή της τοξίνης της διφθερίτιδας) κι ανατοξίνη του τετάνου, ως φέρουσες πρωτεΐνες.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0810894.6A GB0810894D0 (en) | 2008-06-13 | 2008-06-13 | Conjugated saccharide |
EP09762071.0A EP2303333B1 (en) | 2008-06-13 | 2009-06-12 | Conjugated vi saccharides |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1116379T1 true CY1116379T1 (el) | 2017-02-08 |
Family
ID=39672273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20151100416T CY1116379T1 (el) | 2008-06-13 | 2015-05-11 | Συζευγμενοι vi σακχαριτες |
Country Status (18)
Country | Link |
---|---|
US (2) | US20110142876A1 (el) |
EP (1) | EP2303333B1 (el) |
CN (1) | CN102089009B (el) |
AU (1) | AU2009259017B2 (el) |
BR (1) | BRPI0915517B8 (el) |
CA (1) | CA2727565C (el) |
CY (1) | CY1116379T1 (el) |
DK (1) | DK2303333T3 (el) |
ES (1) | ES2537019T3 (el) |
GB (1) | GB0810894D0 (el) |
HR (1) | HRP20150527T1 (el) |
HU (1) | HUE025512T2 (el) |
NZ (1) | NZ590089A (el) |
PL (1) | PL2303333T3 (el) |
PT (1) | PT2303333E (el) |
SI (1) | SI2303333T1 (el) |
WO (1) | WO2009150543A2 (el) |
ZA (1) | ZA201009304B (el) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102120761B (zh) * | 2010-12-24 | 2013-02-06 | 新疆维吾尔自治区畜牧科学院兽医研究所 | 一种无荚膜型金黄色葡萄球菌胞外多糖-蛋白质偶联物的制备方法 |
EP2755683B1 (en) | 2011-09-14 | 2019-04-03 | GlaxoSmithKline Biologicals SA | Methods for making saccharide-protein glycoconjugates |
KR102447303B1 (ko) | 2013-08-24 | 2022-09-23 | 브하라트 바이오테크 인터내셔날 리미티드 | 박테리아성 백신 및 그의 제조방법 |
EP2870974A1 (en) * | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
WO2017187448A1 (en) * | 2016-04-25 | 2017-11-02 | National Institute Of Immunology | A novel conjugate for vaccination against typhoid comprising chemical conjugate of vi polysaccharide and flagellin, a process for producing the same and a composition comprising the conjugate |
FI3506935T3 (fi) | 2016-09-02 | 2024-04-17 | Sanofi Pasteur Inc | Neisseria meningitidis -rokote |
EP4061412A1 (en) | 2019-11-22 | 2022-09-28 | GlaxoSmithKline Biologicals S.A. | Dosage and administration of a bacterial saccharide glycoconjugate vaccine |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL102687A (en) * | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
US5738855A (en) | 1994-10-17 | 1998-04-14 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Synthesis of typhoid fever vaccine from a plant or fruit polysaccharide |
WO2002020059A2 (en) | 2000-09-01 | 2002-03-14 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Vibrio cholerae o139 conjugate vaccines |
AU2002309259A1 (en) * | 2002-05-09 | 2003-11-11 | Massimo Porro | Improved polysaccharide and glycoconjugate vaccines_____________ |
US8048432B2 (en) * | 2003-08-06 | 2011-11-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Polysaccharide-protein conjugate vaccines |
NZ575273A (en) * | 2006-09-07 | 2012-02-24 | Glaxosmithkline Biolog Sa | Method for making combination vaccine comprising inactivated poliovirus type 1, diptheria toxoid and tetanus toxoid |
GB0700135D0 (en) * | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Vaccine |
-
2008
- 2008-06-13 GB GBGB0810894.6A patent/GB0810894D0/en not_active Ceased
-
2009
- 2009-06-12 WO PCT/IB2009/006285 patent/WO2009150543A2/en active Application Filing
- 2009-06-12 SI SI200931193T patent/SI2303333T1/sl unknown
- 2009-06-12 DK DK09762071.0T patent/DK2303333T3/da active
- 2009-06-12 ES ES09762071.0T patent/ES2537019T3/es active Active
- 2009-06-12 EP EP09762071.0A patent/EP2303333B1/en active Active
- 2009-06-12 CA CA2727565A patent/CA2727565C/en active Active
- 2009-06-12 NZ NZ590089A patent/NZ590089A/xx unknown
- 2009-06-12 CN CN2009801278952A patent/CN102089009B/zh active Active
- 2009-06-12 BR BRPI0915517A patent/BRPI0915517B8/pt active IP Right Grant
- 2009-06-12 US US12/997,411 patent/US20110142876A1/en not_active Abandoned
- 2009-06-12 PT PT97620710T patent/PT2303333E/pt unknown
- 2009-06-12 HU HUE09762071A patent/HUE025512T2/hu unknown
- 2009-06-12 AU AU2009259017A patent/AU2009259017B2/en active Active
- 2009-06-12 PL PL09762071T patent/PL2303333T3/pl unknown
-
2010
- 2010-12-23 ZA ZA2010/09304A patent/ZA201009304B/en unknown
-
2012
- 2012-10-26 US US13/661,409 patent/US9475846B2/en active Active
-
2015
- 2015-05-11 CY CY20151100416T patent/CY1116379T1/el unknown
- 2015-05-18 HR HRP20150527TT patent/HRP20150527T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
HRP20150527T1 (en) | 2015-06-19 |
HUE025512T2 (hu) | 2016-05-30 |
CA2727565C (en) | 2017-01-10 |
AU2009259017A1 (en) | 2009-12-17 |
PL2303333T3 (pl) | 2015-11-30 |
WO2009150543A2 (en) | 2009-12-17 |
NZ590089A (en) | 2012-12-21 |
PT2303333E (pt) | 2015-06-08 |
CN102089009A (zh) | 2011-06-08 |
SI2303333T1 (sl) | 2015-06-30 |
US9475846B2 (en) | 2016-10-25 |
ZA201009304B (en) | 2012-08-29 |
AU2009259017B2 (en) | 2014-12-11 |
EP2303333B1 (en) | 2015-02-18 |
ES2537019T3 (es) | 2015-06-01 |
DK2303333T3 (da) | 2015-05-26 |
BRPI0915517A2 (pt) | 2017-06-20 |
GB0810894D0 (en) | 2008-07-23 |
CA2727565A1 (en) | 2009-12-17 |
WO2009150543A3 (en) | 2010-05-06 |
US20130142822A1 (en) | 2013-06-06 |
BRPI0915517B1 (pt) | 2020-10-06 |
CN102089009B (zh) | 2013-12-04 |
BRPI0915517B8 (pt) | 2021-05-25 |
US20110142876A1 (en) | 2011-06-16 |
EP2303333A2 (en) | 2011-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1116379T1 (el) | Συζευγμενοι vi σακχαριτες | |
CY1121376T1 (el) | Εμβολιο προϊοντος συζευξης πνευμονιοκοκκικου πολυσακχαριδιου | |
PE20120582A1 (es) | Conjugados de insulina cristalina | |
UY32933A (es) | Sistema de expresión periplásmico | |
CY1119183T1 (el) | Πεπτιδια λυσοσωμiκης στοχευσης και χρησεις αυτων | |
NZ588884A (en) | Cross-linkers and their uses | |
CY1122895T1 (el) | Στερεες μορφες 3-(6-(1-(2,2-διφθοροβενζο[d][1,3]διοξολ-5-υλο)-κυκλοπροπανοκαρβοξαμιδο)-3-μεθυλοπυριδιν-3-υλο)-βενζοϊκου οξεος | |
EA200800657A1 (ru) | Способ приготовления очищенных конъюгатов лекарственных средств | |
CY1121860T1 (el) | Συνθετικα ενδιαμεσα για την παρασκευη συζευγματων ολιγοσακχαριτη-πρωτεϊνης | |
CY1116901T1 (el) | Εμβολιο που περιλαμβανει προϊοντα συζευξης καψικου πολυσακχαριδιου streptococcus pneumoniae | |
WO2006124737A3 (en) | Molecular constructs suitable for targeted conjugates | |
DK2115191T3 (da) | Cnt-infunderet fiber og fremgangsmåde dertil | |
CY1113435T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει παραγωγο πυραζινης, και μεθοδος χρησης παραγωγου πυραζινης σε συνδυασμο | |
EA201000798A1 (ru) | Производные гидроксиалкил крахмала и способ их получения | |
EA201190283A1 (ru) | Мультивалентный адъювантный дисплей | |
CY1111914T1 (el) | Μεθοδος συνθεσης της ιβαβραδινης και των αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ | |
BRPI0520362A2 (pt) | preparação de conjugados de insulina | |
TR201908333T4 (tr) | Karbonizasyon yöntemi ve cihazı. | |
CY1112869T1 (el) | Υποκατεστημενα με ετεροαρυλιο αμιδια τα οποια περιεχουν μια κεκορεσμενη ομαδα συνδετη και η χρηση τους ως φαρμακα | |
ATE552832T1 (de) | Antidepressivum-propharmaka | |
NO20091386L (no) | Fenyloksyanilinderivater | |
CY1113835T1 (el) | Δραση των εκχυλισματων του φυτου cissampelos pareira εναντι του δαγκειου πυρετου | |
DK2081944T3 (da) | Nye morfin-derivater | |
BRPI0614280A2 (pt) | atorvastatina sódica cristalina e amorfa | |
UA104146C2 (ru) | ПОЛИМЕРНЫЕ КОНЪЮГАТЫ ФРАГМЕНТОВ ИНТЕРФЕРОНА-β, ЭРИТРОПОЭТИНА И ГОРМОНА РОСТА |